Vanucizumab
Vanucizumab Basic information
- Product Name:
- Vanucizumab
- Synonyms:
-
- Vanucizumab
- Research Grade Vanucizumab (DHA42302)
- Research Grade Vanucizumab
- CAS:
- 1448221-05-3
- MW:
- 0
- Mol File:
- Mol File
Vanucizumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Vanucizumab Usage And Synthesis
Uses
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects[1].
in vivo
Vanucizumab (20 mg/kg; i.p.; once weekly; for 6 weeks) shows tumor growth inhibition and induces tumor stasis[2].
| Animal Model: | SCID beige mice bearing Colo205 cells[2] |
| Dosage: | 20 mg/kg |
| Administration: | i.p.; once weekly; for 6 weeks |
| Result: | Showed tumor growth inhibition. |
References
[1] Manuel Hidalgo, et al. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 Apr 1;24(7):1536-1545. DOI:10.1158/1078-0432.CCR-17-1588
[2] Wolfgang Schaefer, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92. DOI:10.1073/pnas.1019002108
VanucizumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com